Autoimmune Disease

Autoimmune Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Genetic polymorphisms associated with rheumatoid arthritis, metods of detection and uses thereof
May 25, 2017 - N°20170145503

The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules ...
NEW Use of mcoln-1 modulators to regulate cell migration
May 25, 2017 - N°20170145423

The present invention relates to the use of modulators of mcoln-1 for modulating the cells migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune diseases treatment, and metastasis prevention.
NEW Inhibitor of bruton's tyrosine kinase
May 25, 2017 - N°20170144986

Provided are a compound represented by formula (iii) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (iii), and the application of the pharmaceutical compositions as selective inreversible inhibitor of bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with ...
NEW Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Rituximab induction therapy followed by glatiramer acetate therapy
May 25, 2017 - N°20170143824

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The ...
NEW Compositions comprising bacterial strains
May 25, 2017 - N°20170143775

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
NEW Compositions comprising bacterial strains
May 25, 2017 - N°20170143774

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
NEW Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy ...
May 25, 2017 - N°20170143712

In an embodiment, therapeutic methods and uses of bruton's tyrosine kinase (btk) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on btk occupancies and/or btk resynthesis rates for b cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for ...
Antibodies to il-15
Calypso Biotech Sa
May 18, 2017 - N°20170137511

The present invention relates to antibodies binding il-15, in particular humanized antibodies. In particular, the anti-il-15 antibodies according to the invention are able to neutralize il-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or ...
Kv1.3 potassium channel antagonists
Conogenetix Biosciences Gmbh
May 18, 2017 - N°20170137470

The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel kv1. 3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection.
Treatment of autoimmune diseases with deep brain stimulation
Aleva Neurotherapeutics
May 18, 2017 - N°20170136238

Techniques using electrical stimulation for treating an autoimmune disease by means of an implantable pulse generator and at least one electrode. An electrode lead is surgically implanted in a region of the insular cortex to deliver electrical stimulation. The at least one electrode lead and implantable pulse generator contain features that allow the electrical stimulation to be directed to specific ...
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or ...
Prothena Biosciences Limited
May 11, 2017 - N°20170129954

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory ...
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
Kolltan Pharmaceuticals, Inc.
May 11, 2017 - N°20170129947

The present disclosure provides methods for modulating the interaction between a tam ligand and a lipid membrane containing phosphatidyl serine (ptdser). In one example, such methods use a tam receptor agonist having a ptdser-containing lipid bilayer membrane with gas6 and/or protein s bound to the membrane to activate signaling from one or more tam receptors and treat an autoimmune ...
Heterocyclic compounds as pi3k-y inhibitors
Kolltan Pharmaceuticals, Inc.
May 11, 2017 - N°20170129899

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method of isolating sphingolipids from cordyceps and their use
Macau University Of Science And Technology
May 11, 2017 - N°20170128507

A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from cordyceps, in particular from wild-type cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not ...
Phosphatidylglycerol as an anti-inflammatory
Agusta University Research Institute, Inc.
May 11, 2017 - N°20170128468

Compositions and methods for reducing, or inhibiting inflammation in a subject in need thereof have been developed. Pharmaceutical compositions including one or more phosphatidylglycerol (pg), or functional derivatives thereof, in an effective amount to reduce or inhibit inflammation are provided. The compositions are particularly suited for treating inflammation associated with the skin such as psoriasis, or inflammation associated with the ...
Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive ...
Universite D'aix-marseille
May 11, 2017 - N°20170128433

The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the pp1/gadd34 ...
Antibody which specifically binds to human crth2
Kyowa Hakko Kirin Co., Ltd
May 04, 2017 - N°20170121415

There is provided an anti-human crth2 antibody which has desired activity by recognizing and binding to a specific human crth2; the antibody fragment; dna which encodes the amino acid sequence of the antibody; a vector which comprises the dna; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody ...
Using b-cell-targeting antigen igg fusion as tolerogenic protein therapy for treating adverse immune responses
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
May 04, 2017 - N°20170121379

The present invention generally relates to antigen-specific tolerogenic protein therapy and the use thereof for treating adverse immune responses, including those associated with autoimmune diseases such as multiple sclerosis (ms) and hemophilia. In particular, the invention involves the application of a b cell-targeting igg fusion protein as the antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies. ...
Amino sphingoglycolipid analogues
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
May 04, 2017 - N°20170119875

The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.
Lanthionine synthetase c-like 2-based therapeutics
Biotherapeutics, Inc.
May 04, 2017 - N°20170119762

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
Anti-il-2 antibodies and compositions and uses thereof
The Board Of Trustees Of The Leland Stanford Junior University
April 27, 2017 - N°20170114130

The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to il-2 and reduce the affinity of il-2 binding to il-2rα and il-2rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these ...